EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease

Didem Akkaya iD, Gökçe Seyhan iD, Suat Sari iD, Burak Barut iD

Drug Development Research · 2024-05 · 85 (3)

DOI: 10.1002/ddr.22184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 18.04.2024. Verfasst von Didem Akkaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Biochemistry, Karadeniz Technical University, Trabzon, Turkey. Hauptthemen laut MEDLINE: Alzheimer Disease, Trimebutine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD), one of the main causes of dementia, is a neurodegenerative disorder. Cholinesterase inhibitors are used in the treatment of AD, but prolonged use of these drugs can lead to serious side effects. Drug repurposing is an approach that aims to reveal the effectiveness of drugs in different diseases beyond their clinical uses. In this work, we investigated in vitro and in silico inhibitory effects of 11 different drugs on cholinesterases. The results showed that trimebutine, theophylline, and levamisole had the highest acetylcholinesterase inhibitory actions among the tested drugs, and these drugs inhibited by 68.70 ± 0.46, 53.25 ± 3.40, and 44.03 ± 1.20%, respectively at 1000 µM. In addition, these drugs are bound to acetylcholinesterase via competitive manner. Molecular modeling predicted good fitness in acetylcholinesterase active site for these drugs and possible central nervous system action for trimebutine. All of these results demonstrated that trimebutine was determined to be the drug with the highest potential for use in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseTrimebutineHumansAcetylcholinesteraseCholinesterase InhibitorsModels, MolecularMolecular Docking Simulation

Stichwörter der Autor:innen

Alzheimer's diseasecholinesterasescompetitive mannerdrug repurposing

Substanzen

AcetylcholinesteraseTrimebutineCholinesterase Inhibitors

Autor:innen und Institutionen

  • Faculty of Pharmacy, Department of Biochemistry, Karadeniz Technical University, Trabzon, Turkey.
  • Faculty of Pharmacy, Pharmaceutical Chemistry Department, Hacettepe University, Ankara, Turkey.

ORCID-Profile: Didem Akkaya, Gökçe Seyhan, Suat Sari, Burak Barut

Zitieren

APA

Akkaya, D., Seyhan, G., Sari, S., & Barut, B. (2024). In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease. Drug Development Research, 85(3). https://doi.org/10.1002/ddr.22184

Vancouver

Akkaya D, Seyhan G, Sari S, Barut B. In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease. Drug Development Research. 2024;85(3). doi:10.1002/ddr.22184

BibTeX
@article{Akkaya2024,
  author = {Akkaya, Didem and Seyhan, Gökçe and Sari, Suat and Barut, Burak},
  title = {In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease},
  journal = {Drug Development Research},
  year = {2024},
  volume = {85},
  number = {3},
  doi = {10.1002/ddr.22184}
}
Kostenlos starten →